China bans surgical treatment of Alzheimer's
The procedure, known as
lymphatic-venous anastomosis
(LVA), involves connecting the patient's lymph vessels to veins near the neck to speed up the flow and drainage of lymph fluid. The aim is to boost the removal of harmful brain proteins and slow the disease's progression.
The National Health Commission said it has recently learned that some medical institutions are conducting lymphaticovenous anastomosis, also known as LVA surgery, on patients diagnosed with Alzheimer's disease.
Following the commission's discovery, it conducted assessments on the procedure's safety and efficacy, the Commission said in a notice.
"Our evaluation concludes that there is a lack of evidence from preclinical studies in the use of LVA surgery for
Alzheimer's disease treatment
," it said, state-run China Daily reported on Friday.
"The procedure remains at an early stage of clinical research with its indications and contraindications yet to be clarified, and there is insufficient medical or health economic evidence attesting to its safety, efficacy and cost-effectiveness," the commission added.
Local health authorities are advised to instruct medical institutions to halt treating Alzheimer's disease with LVA surgery and guarantee proper follow-up care for affected patients.
"When sufficient preclinical evidence is collected, qualified medical institutions can carry out clinical studies under the full deliberation of ethics committees," it added.
The surgery has grown in popularity, particularly over the past year, since it was first performed in 2021 by a microsurgery expert from a private hospital in Hangzhou, in the eastern province of Zhejiang.
Based on publicly available information, an estimated 382 hospitals across almost all Chinese provinces had performed the procedure by the end of June, the Hong Kong-based South China Morning Post reported.
Alzheimer's disease - the leading cause of dementia - is a brain disorder that slowly destroys memory and thinking skills, and eventually the ability to carry out the simplest tasks.
When the surgery first came to public attention, some Chinese doctors promoted it enthusiastically on social media, claiming it was "effective for 60 to 80 per cent of patients", according to the Post report.
But it has also been met with scepticism, with some medical experts questioning its fundamental mechanism and long-term effectiveness.
Dr Fan Dongsheng, a professor in the neurology department at Peking University Third Hospital, warned that the scientific mechanism behind the treatment had not been well studied and was at present not convincing.
He told the Post that the reported improvements in patient symptoms were qualitative and not based on the accepted evaluation system.
Fan welcomed the government's decision to halt the treatment, calling it "apparently problematic" that many hospitals, even small ones, performed the surgery extensively without solid evidence and had charged patients for it.
Users on the Chinese social media platforms, however, expressed their anxiety that diagnosed family members would no longer be able to receive the treatment.
"If the patient's family agrees, I think it's worth trying because some patients are in a really serious condition and their families are exhausted and desperate," a person from northeastern Liaoning wrote.
One man said that his father, who was treated in March, had recovered well and could now recognise people and look after himself.
If surgery had the potential to improve patients' conditions, "most families would choose to give it a try", he told the Post. PTI
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Hindu
an hour ago
- The Hindu
Facial, speech problems among after-effects of mucormycosis post recovery: ICMR study
People who suffered from mucormycosis and recovered continue to battle long-term health effects of the fungal infection, such as facial disfigurement and speech difficulty, found an ICMR study. There was an uptick in cases of mucormycosis, a rare infection also known as 'Black Fungus', during the COVID-19 pandemic. Published last month in Clinical Microbiology and Infection, a leading microbiology journal, the study found that 14.7 per cent of 686 hospitalised mucormycosis patients died within a year, with most deaths occurring during initial hospitalisation. Critical predictors of poor survival included involvement of the brain or eyes, intensive care admission, poor glycaemic control, and comorbid conditions. Conversely, patients who received both surgical treatment and combination antifungal therapy (particularly Amphotericin-B formulations with Posaconazole) had significantly higher survival rates, said Dr Rizwan Suliankatchi Abdulkader, from ICMR's National Institute of Epidemiology (NIE), the lead author of the study. "But survivors often faced disfigurement and psychological distress, with more than 70 per cent reporting at least one clinical sequela (complication or disability) and a substantial proportion experiencing loss of employment," Rizwan said. 'These are not abstract complications. Facial disfigurement, impaired speech, anxiety, and loss of livelihood are lived realities for many survivors. It is time for India to move beyond life-saving interventions and focus on life-restoring systems of care, including mental health support and rehabilitation,' he said. Led by Rizwan and the All-India Mucormycosis Consortium, the study assessed survival, treatment outcomes, and post-recovery quality of life among hospitalised patients in India. This large-scale study, covering 686 patients from 26 tertiary hospitals across the country, is the first of its kind to offer long-term, prospective data on this critical public health concern. As a part of the study, 686 patients who had contracted mucormycosis between March and July 2021 were followed up for one year. Of the 686, 80 per cent (549) also had COVID-19. The prevalence of mucormycosis varies significantly, from 0.01 to 2 cases per million in developed countries to 140 cases per million in India and similar nations, with incidence approximately 80 times higher in India. Despite advances in medical care, mucormycosis remains a highly lethal and debilitating condition. 'This study reinforces the pressing need to ensure access to timely diagnosis, surgical interventions, and combination antifungal therapy in all parts of India," said Dr Manoj Murhekar, Director of Chennai-based ICMR-NIE. "We cannot overstate how essential high-quality, multidisciplinary care is for patients battling mucormycosis, especially given the irreversible complications they face if treatment is delayed," said Murhekar, a senior author of the study. Spanning the length and breadth of India, the study involved institutions from nearly every region, capturing a diverse and realistic picture of mucormycosis management in both urban and rural populations. Rizwan stressed, 'This is not just a story of numbers. Behind every data point is a person who struggled with pain, disfigurement, and long-term disability. Our duty as clinicians and public health professionals is to reduce not just mortality but also the suffering that comes with survival. "India has a disproportionately high burden of this disease. Our health systems must be better prepared.' The research comes at a time when India is still grappling with the long-term fallout of the COVID-19 pandemic, during which mucormycosis surged dramatically. As the global community turns its attention to pandemic preparedness and health system resilience, the study serves as a sobering reminder of the challenges posed by neglected fungal diseases. 'We hope our findings will serve as a call to action for policymakers, hospital administrators, and clinicians. Mucormycosis is not just a complication of COVID-19. It is a disease that demands long-term clinical attention, public health surveillance, and above all, compassion in care," Rizwan said.
Mint
an hour ago
- Mint
Cipla to enter into weight management segment in India, says MD Umang Vohra
Drugmaker Cipla's MD and global CEO Umang Vohra has announced that the company is planning to enter into the weight management segment in India. The pharma major is also strengthening its presence in the central nervous system (CNS) therapeutic area, Vohra stated in the company's Annual Report for 2024-25. "Our efforts are rooted in understanding patient needs, reducing stigma, and delivering differentiated therapies for niche is emerging as a priority area for Cipla. With a clear strategic intent, we are preparing to enter the weight management segment in India, aiming to address the rising demand for effective obesity solutions," Vohra said. In the CNS segment, the Mumbai-based company has successfully in-licensed Sanofi India's CNS product range, including Frisium, a leading brand in the anti-epileptic category, he added. He also said: "Building on this momentum, we aim to pursue similar in-licensing deals or acquisitions in niche indications of attention deficit hyperactivity disorder (ADHD) and Parkinson's disease." Several domestic pharma companies are developing drugs for weight loss to capitalise on the growing market for obesity and diabetes management. American drugmaker Eli Lilly & Co has already launched its anti-obesity drug Mounjaro in India. Denmark's Novo Nordisk has also launched its anti-obesity drug Wegovy, indicated for both long-term chronic weight management and reduction in risk of major adverse cardiovascular events. For fiscal year 2025, Cipla reported consolidated revenue of ₹ 27,548 crore. Its consolidated net profit increased to ₹ 5,272 crore. Umang Vohra further said the company is equally committed to addressing the global crisis of anti-microbial resistance (AMR). "Our AMR portfolio is evolving from volume-based to innovation-led, with four novel products in development," he said. "We will continue to invest in big brands, strategic alliances, digital infrastructure, and next-generation therapies, while remaining rooted in our founding values of care and compassion," he added.
Hindustan Times
an hour ago
- Hindustan Times
Hepatologist explains how gut influences memory, mood and mental wellbeing; unpacks why gut may be the ‘second brain'
Several cognitive functions, such as memory, thinking, and concentration, don't just stem from brain activity alone; they are also deeply influenced by gut health. This further demonstrates the importance of gut health in maintaining overall well-being, as it has the ability to influence major functions, including immunity and mental performance. In an interview with HT Lifestyle, Dr Amey Sonavane, consultant hepatology, AHNM, explained how key brain functions are connected to gut health. From memory to concentration, much of the cognitive functions are influenced by gut health. (Shutterstock) ALSO READ: Gastroenterologist shares what your stool's colour, consistency, and frequency tell about your gut health He said, 'Memory and brain function are also closely linked to gut health. The gut sends signals to the brain that affect focus, memory, and even decision-making. When gut bacteria are in poor shape, they can produce chemicals that travel through the bloodstream to the brain, potentially increasing inflammation and contributing to cognitive decline. Some early studies suggest that changes in gut bacteria may appear even before signs of memory loss or Alzheimer's disease show up. This makes the gut an important area to watch, not just for digestion, but for long-term brain health.' Let's take a closer look at the gut-brain axis and explore the fundamentals of this connection, from the microbiome and the chemicals that make the gut the 'second brain' to how your diet can help support this bi-directional relationship. Role of microbiome The microbiome is one of the vital factors at play that form the bedrock of the gut-brain axis, shaping and influencing major cognitive functions and mood regulation. While the gut-brain axis may seem complex, the gut microbiome holds the answers and simplifies it. Dr Amey spoke about the role of microbiome and explained, 'Over the past few years, scientists have discovered something quite remarkable - your gut does a lot more than digest food. Inside your digestive system lives a massive population of bacteria and other tiny organisms, collectively called the gut microbiome. These microorganisms affect how you feel, how your body handles food, and even how your brain works. In simple terms, your gut could be quietly shaping your mood, metabolism, and memory every single day.' Gut is the second brain for mood The roots of your happy moods may be in your gut.(Shutterstock) While cognitive functions like memory, concentration, attention, decision-making, and processing are shaped by gut health, even emotions can be influenced by what's going on in your gut. It signifies the powerful role of gut health, influencing both mind and mood. Dr Amey shed light on the connection to mood regulation and said, 'The gut and the brain are constantly in touch with each other through a network known as the gut-brain axis. In fact, the gut is often called the 'second brain' because it produces many of the same chemicals that your brain does.' 'For example, about 90 percent of your body's serotonin, a chemical that influences mood, is made in the gut. It regulates things like gut motility, secretion, and blood clotting. If the balance of bacteria in your gut is disturbed, it can trigger low moods, anxiety, or even depression. New research shows that improving gut health can actually help some people feel mentally better, giving rise to what are now being called 'psychobiotics', probiotics that support mental health,' he added. Brain-friendly foods Curd in Indian dishes like raita contains good bacteria that help to balance the oral microbiome. (Shutterstock) If the role of gut health in mental wellbeing feels intimidating because it's something that is beyond your conscious control and awareness, but it turns out you can actively take charge and consciously support this gut-brain axis by adding gut-healthy food to your diet. The hepatologist shared some gut-healthy foods and warned against one common habit. Dr Amey suggested, 'Traditional Indian diets actually offer a natural advantage. Fermented foods like curd, buttermilk, dosa, and idli are full of beneficial bacteria. Fruits, vegetables, whole grains, and lentils feed the good microbes in your gut and help keep harmful ones in check. On the other hand, overuse of antibiotics, low-fibre diets, stress, and lack of physical activity can damage the microbiome.' Note to readers: This article is for informational purposes only and not a substitute for professional medical advice. Always seek the advice of your doctor with any questions about a medical condition.
